<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04646811</url>
  </required_header>
  <id_info>
    <org_study_id>35RC18_8851_TRI-FR</org_study_id>
    <secondary_id>2020-A00645-34</secondary_id>
    <nct_id>NCT04646811</nct_id>
  </id_info>
  <brief_title>Evaluation of Tricuspid Valve Percutaneous Repair System in the Treatment of Severe Secondary Tricuspid Disorders</brief_title>
  <acronym>TRI-FR</acronym>
  <official_title>TRI-FR : Multicentric Randomized Evaluation of Tricuspid Valve Percutaneous Repair System (Clip for the Tricuspid Valve) in the Treatment of Severe Secondary Tricuspid Disorders</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rennes University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rennes University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Tricuspid regurgitation (TR) is a long-overdue valvular pathology. Its prevalence is&#xD;
      significant and increasing with the aging of the population. It is often a consequence of&#xD;
      chronic left cardiac pathologies or atrial fibrillation. Surgical treatment is recommended in&#xD;
      severe symptomatic TR or when the tricuspid annulus is dilated with TR identified prior to&#xD;
      scheduled left heart valve surgery. TR are mainly secondary (complicating left heart disease,&#xD;
      pulmonary hypertension, atrial fibrillation and atrial dilatation) and pose a difficult&#xD;
      problem related to the prognosis. The risk of death or hospitalization is high under medical&#xD;
      treatment. Nevertheless, the surgical results are disappointing with significant morbidity&#xD;
      and mortality, which are increased by associated comorbidities that are frequent in these&#xD;
      sorts of patients. The benefit-risk assessment of surgery is limited by multiple confounders.&#xD;
&#xD;
      This justifies the evaluation of alternative methods aimed at correcting TR with less&#xD;
      interventional risk.&#xD;
&#xD;
      The Clip for the tricuspid valve has been evaluated in the TRILUMINATE trial (inclusion of 85&#xD;
      patients with moderate-to-severe symptomatic TR with a 6-month follow-up). The Triclip system&#xD;
      appears to be safe and effective at reducing tricuspid regurgitation by at least one grade.&#xD;
      This reduction could translate to significant clinical improvement at 6 months&#xD;
      post-procedure. It justified the European Conformity (CE) mark obtention.&#xD;
&#xD;
      A very similar system for the mitral valve (Mitraclip) was previously tested in the&#xD;
      randomized EVEREST II study against conventional surgery. The results of the EVEREST II trial&#xD;
      justified the recourse to percutaneous edge-to edge mitral repair in patients with primary&#xD;
      mitral regurgitation when the patient is contraindicated to conventional surgery.&#xD;
&#xD;
      The Mitra-FR study made it possible to study the role of Mitraclip for treating patient&#xD;
      suffering from a secondary mitral insufficiency. It leads to the implementation of this&#xD;
      technique in selected patients.&#xD;
&#xD;
      For secondary TR, several series underscored its prevalence and its clinical consequences. TR&#xD;
      treatment justifies the proposal for a randomized study. As a matter of fact, evidence for&#xD;
      treating are seriously lacking. Surgical surveys report hospital mortality ~ 8.8%. It,&#xD;
      therefore, seems necessary to conduct a study as robust as possible to evaluate the&#xD;
      contribution of clip for the tricuspid valve (as an innovative percutaneous technique)&#xD;
      compared to conventional pharmacological treatment in patients who are unsuitable for a&#xD;
      surgical isolated correction of the TR and who has suitable anatomy for clip for the&#xD;
      tricuspid valve. It will be necessary to demonstrate clinical, functional (quality of life),&#xD;
      echocardiographic and biological benefit of the percutaneous treatment vs optimized medical&#xD;
      treatment alone.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The principal objective is to demonstrate, over a period of 12-month after randomization,&#xD;
      that, on the Packer composite clinical endpoint (CCS) (combining NYHA class, patient global&#xD;
      assessment (PGA) and major cardio-vascular events), the tricuspid valve percutaneous repair&#xD;
      strategy with clip for the tricuspid valve is superior to best (optimized) medical treatment&#xD;
      (BMT) in symptomatic patients with at least severe secondary TR. The Packer clinical&#xD;
      composite score is eventually a three-level ordered categorical endpoint, each randomized&#xD;
      patient being classifying as improved, unchanged, or worsen, depending on the clinical&#xD;
      response over the follow-up period and at 12 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 10, 2021</start_date>
  <completion_date type="Anticipated">August 2025</completion_date>
  <primary_completion_date type="Anticipated">February 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Milton Packer clinical composite score</measure>
    <time_frame>12 months</time_frame>
    <description>Milton Packer clinical composite score classifies each patient into 1 of 3 categories (improved, worsened, unchanged), and is determined aggregating evaluation functional using NYHA class, quality of life score using patient global assessment and number of major cardio-vascular events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>number of participants with all-cause mortality</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of participants with tricuspid valve surgery</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>rate of heart failure hospitalizations</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>assessment of quality of life improvement</measure>
    <time_frame>0 and 12 months</time_frame>
    <description>Kansas City Cardiomyopathy Questionnaire score (KCCQ) The responses are categorized under 3 subscales (symptom burden, physical limitation and quality of life) with a range of possible subscale scores from 0 to 100, with 100 representing the least burden of symptoms. The total KCCQ score represents the mean of the three subscale scores.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>quality of life score</measure>
    <time_frame>6 and 12 months</time_frame>
    <description>Kansas City Cardiomyopathy Questionnaire (KCCQ) The responses are categorized under 3 subscales (symptom burden, physical limitation and quality of life) with a range of possible subscale scores from 0 to 100, with 100 representing the least burden of symptoms. The total KCCQ score represents the mean of the three subscale scores.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>quality of life score</measure>
    <time_frame>6 and 12 months</time_frame>
    <description>Minnesota Living with Heart Failure (MLHF)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>quality of life score</measure>
    <time_frame>6 and 12 months</time_frame>
    <description>EQ5D-5L The EQ-5D-5L consists of the EQ-5D descriptive system and the EQ visual analogue scale (EQ VAS).&#xD;
The descriptive system :&#xD;
5 dimensions : mobility, self-care, usual activities, pain/discomfort, anxiety/depression.&#xD;
5 levels : no problems,slight problems, moderate, problems and extreme. Each level corresponds to 1 digit number. The digits for the 5 dimensions are combined into a 5-digit number.&#xD;
The EQ VAS : on a vertical visual analogue scale, 100 'The best health you can imagine' 0 'The worst health you can imagine'.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>quality of life score</measure>
    <time_frame>6 and 12 months</time_frame>
    <description>Patient global assessment (PGA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>functional evaluation</measure>
    <time_frame>6 and 12 months</time_frame>
    <description>NYHA functional class</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>severity of the Tricuspid Regurgitation (TR)</measure>
    <time_frame>6 and 12 months</time_frame>
    <description>TR grade</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>walking distance</measure>
    <time_frame>6 and 12 months</time_frame>
    <description>6-minute walk test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>echocardiography parameters</measure>
    <time_frame>6 and 12 months</time_frame>
    <description>right heart function</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>echocardiography parameters</measure>
    <time_frame>6 and 12 months</time_frame>
    <description>right heart cavities sizes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>echocardiography parameters</measure>
    <time_frame>6 and 12 months</time_frame>
    <description>degree of tricuspid regurgitation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>echocardiography parameters</measure>
    <time_frame>6 and 12 months</time_frame>
    <description>stenosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>biological parameters</measure>
    <time_frame>6 and 12 months</time_frame>
    <description>parameters renal : creatinine, clearance, AST</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>biological parameters</measure>
    <time_frame>6 and 12 months</time_frame>
    <description>hepatic function</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>biological parameters</measure>
    <time_frame>6 and 12 months</time_frame>
    <description>NT-proBNP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>6 and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of cardiovascular death</measure>
    <time_frame>6 and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of major cardiovascular events</measure>
    <time_frame>6 and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incremental Cost-Effectiveness Ratio expressed as cost per QALY</measure>
    <time_frame>12 and 24 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Tricuspid Regurgitation</condition>
  <arm_group>
    <arm_group_label>Tricuspid valve</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>tricuspid valve percutaneous repair strategy with clip for the tricuspid valve</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Best medical treatment</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Tricuspid valve</intervention_name>
    <description>Clip for the tricuspid valve implantation on top of best medical therapy</description>
    <arm_group_label>Tricuspid valve</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Best medical treatment</intervention_name>
    <description>Best medical therapy alone</description>
    <arm_group_label>Best medical treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Pre-Inclusion Criteria:&#xD;
&#xD;
          1. Age &gt; 18 years&#xD;
&#xD;
          2. Symptomatic secondary (at least) severe TR (Carpentier Type IIIB (restrictive) and /&#xD;
             or I (tricuspid annulus dilation)) stable for at least 30 days&#xD;
&#xD;
          3. NYHA functional class II to IV without cirrhosis and/or ascites&#xD;
&#xD;
          4. Signs of heart failure in the previous 12-months with or without having been&#xD;
             hospitalized&#xD;
&#xD;
          5. Stable optimized medical and/or interventional treatment&#xD;
&#xD;
          6. Ineligible for corrective action on the valve by surgical approach after a specialized&#xD;
             multidisciplinary consultation (&quot;heart team&quot;) including at least a cardio-thoracic&#xD;
             surgeon, an interventional cardiologist, an imaging-cardiologist and an&#xD;
             Anesthesiologist).&#xD;
&#xD;
          7. Signature of an informed consent&#xD;
&#xD;
             Definitive Inclusion Criteria:&#xD;
&#xD;
          8. Central core-laboratory analysis : TR characterized before Implantation by at least&#xD;
             one of the following criteria:&#xD;
&#xD;
               -  Regurgitation volume &gt; 45 mL / beat&#xD;
&#xD;
               -  Surface of the regurgitant orifice &gt; 40 mm²&#xD;
&#xD;
               -  Vena contracta&gt; 7mm&#xD;
&#xD;
               -  Gap between leaflets ≤ 7 mm&#xD;
&#xD;
        Then after the TR severity grading; the Clinical eligibility Committee will valid the&#xD;
        inclusion.&#xD;
&#xD;
        Non Inclusion Criteria:&#xD;
&#xD;
          1. Patient treated with Mitraclip or other percutaneous approach on the mitral valve in&#xD;
             the past 3-month&#xD;
&#xD;
          2. Any prior tricuspid valve procedure that would interfere with placement of the Triclip&#xD;
             device&#xD;
&#xD;
          3. Tricuspid valve leaflet anatomy which may preclude clip implantation, proper clip&#xD;
             positioning on the leaflets or sufficient reduction in TR. This may include:&#xD;
&#xD;
               -  Tricuspid valve anatomy not evaluable by TTE and TEE&#xD;
&#xD;
               -  Active endocarditis&#xD;
&#xD;
               -  Evidence of calcification in the grasping area&#xD;
&#xD;
               -  Evidence of stenosis (mean pressure gradient &gt; 5 mmHg or surface area ≤1cm²&#xD;
&#xD;
               -  Presence of a severe coaptation defect (&gt; 2cm) of the tricuspid leaflets&#xD;
&#xD;
               -  Severe leaflet defect(s) preventing proper device placement&#xD;
&#xD;
               -  Epstein anomaly - identified by having a normal annulus position while the valve&#xD;
                  leaflets are attached to the walls and septum of the right ventricle&#xD;
&#xD;
          4. Myocardial infarction or coronary bypass surgery in the past 3-month&#xD;
&#xD;
          5. Left ventricular ejection fraction ≤20%&#xD;
&#xD;
          6. Cardiac Resynchronization therapy for less than 3-month and patients having a TR that&#xD;
             is clearly related to the right ventricular lead positioning&#xD;
&#xD;
          7. Cardioversion for less than 6 weeks&#xD;
&#xD;
          8. Life expectancy irrespective of the valvular heart disease &lt;1 year (due to&#xD;
             co-morbidities)&#xD;
&#xD;
          9. Other scheduled cardiac surgery (including registration in cardiac transplant list)&#xD;
&#xD;
         10. Coronary angioplasty in the preceding month&#xD;
&#xD;
         11. Current infection requiring prescription of antibiotics&#xD;
&#xD;
         12. End-stage renal failure (dialysis patient)&#xD;
&#xD;
         13. Severe hepatic insufficiency (disruption of liver metabolism associated with&#xD;
             coagulation disorders (factor V &lt;50%))&#xD;
&#xD;
         14. Stroke in the previous 3-month&#xD;
&#xD;
         15. Uncontrolled pre- capillary pulmonary hypertension (right catheterization required)&#xD;
             (systolic pulmonary pressure &gt; 60 mmHg)&#xD;
&#xD;
         16. Mechanical prosthetic valve&#xD;
&#xD;
         17. Pace maker lead or ICD lead that would prevent appropriate placement of the Triclips&#xD;
&#xD;
         18. Nitinol allergy&#xD;
&#xD;
         19. Contraindication, allergy or hypersensibility to dual anti-platelet and anticoagulant&#xD;
             therapy&#xD;
&#xD;
         20. Ongoing infection requiring antibiotic therapy&#xD;
&#xD;
         21. Evidence of intra vascular or intra cardiac thrombus&#xD;
&#xD;
         22. Patient who are included in another research protocol&#xD;
&#xD;
         23. Protected person (adults legally protected (under judicial protection, guardianship or&#xD;
             supervision), person deprived of their liberty, pregnant woman, lactating woman and&#xD;
             minor)&#xD;
&#xD;
         24. Absence of coverage by a social security scheme&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Donal Erwan</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Rennes</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mevel Nicolas</last_name>
    <phone>02 99 28 25 55</phone>
    <email>dri@chu-rennes.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ganivet Anne</last_name>
    <phone>02 99 28 25 55</phone>
    <email>anne.ganivet@chu-rennes.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Brussel</name>
      <address>
        <city>Bruxelles</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>COSYNS Bernard</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Liège</name>
      <address>
        <city>Liège</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>LANCELLOTTI Patrizio</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Angers</name>
      <address>
        <city>Angers</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>ROULEAU Frédéric</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Bordeaux - Hôpital Cardiologique du Haut-Lévêque</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>LAFITTE Stéphane</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Lille</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>COISNE Augustin</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospices Civils de Lyon Groupement Hospitalier EST</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>OBADIA Jean-François</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>APHM - Hôpital La Timone</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>HABIB Gilbert</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinique du Millénaire</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>SPORTOUCH -DUKHAN Catherine</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Nantes - Hôtel Dieu et Hôpital Nord Laennec</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>CUEFF Caroline</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Bichat</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>DUCROCQ Grégory</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Européen Georges Pompidou</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>KARAM Nicole</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Mutualiste Montsouris</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>DIAKOV Christelle</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Rennes - Hôpital Pontchaillou</name>
      <address>
        <city>Rennes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>DONAL Erwan</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Cardiologique du Nord</name>
      <address>
        <city>Saint-Denis</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>DREYFUS Julien</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Toulouse - Hôpital Rangueil</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>LAVIE-BADIE Yoan</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinique Pasteur</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>TCHETCHE Didier</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Tours - Hôpital Trousseau</name>
      <address>
        <city>Tours</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>BERNARD Anne</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Médipôle Lyon-Villeurbanne</name>
      <address>
        <city>Villeurbanne</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>LEROUX Pierre-Yves</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>November 10, 2020</study_first_submitted>
  <study_first_submitted_qc>November 23, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 30, 2020</study_first_posted>
  <last_update_submitted>April 27, 2021</last_update_submitted>
  <last_update_submitted_qc>April 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>secondary Tricuspid Regurgitation</keyword>
  <keyword>least severe Tricuspid Regurgitation</keyword>
  <keyword>symptomatic patients</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tricuspid Valve Insufficiency</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

